Neuronetics Financials
| STIM Stock | USD 3.41 0.21 6.56% |
Neuronetics |
Neuronetics Stock Summary
Neuronetics competes with Burning Rock, DarioHealth Corp, Sera Prognostics, Biodesix, and Fonar. Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. Neuronetics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 198 people.Specialization | Healthcare, Diagnostics & Research |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US64131A1051 |
| CUSIP | 64131A105 |
| Location | Pennsylvania; U.S.A |
| Business Address | 3222 Phoenixville Pike, |
| Sector | Health Care Equipment & Supplies |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | neurostar.com |
| Phone | 610 640 4202 |
| Currency | USD - US Dollar |
Neuronetics Key Financial Ratios
Neuronetics Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Neuronetics's current stock value. Our valuation model uses many indicators to compare Neuronetics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neuronetics competition to find correlations between indicators driving Neuronetics's intrinsic value. More Info.Neuronetics is rated below average in return on equity category among its peers. It is rated fifth in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Neuronetics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Neuronetics Systematic Risk
Neuronetics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Neuronetics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Neuronetics correlated with the market. If Beta is less than 0 Neuronetics generally moves in the opposite direction as compared to the market. If Neuronetics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Neuronetics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Neuronetics is generally in the same direction as the market. If Beta > 1 Neuronetics moves generally in the same direction as, but more than the movement of the benchmark.
Neuronetics January 31, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Neuronetics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Neuronetics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Neuronetics based on widely used predictive technical indicators. In general, we focus on analyzing Neuronetics Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Neuronetics's daily price indicators and compare them against related drivers.
| Downside Deviation | 10.36 | |||
| Information Ratio | 0.2298 | |||
| Maximum Drawdown | 45.79 | |||
| Value At Risk | (9.45) | |||
| Potential Upside | 18.5 |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Medical Equipment space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuronetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neuronetics is measured differently than its book value, which is the value of Neuronetics that is recorded on the company's balance sheet. Investors also form their own opinion of Neuronetics' value that differs from its market value or its book value, called intrinsic value, which is Neuronetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuronetics' market value can be influenced by many factors that don't directly affect Neuronetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuronetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.